Nutritional and Body Composition Changes in Paediatric β-Thalassemia Patients Undergoing Hematopoietic Stem Cell Transplantation: A Retrospective Study Using Bioelectrical Impedance Analysis

Luyang Zhang,Li Wang,Jiewen Long,Yan Yin,Sandip Patil
DOI: https://doi.org/10.2147/jmdh.s463796
2024-05-09
Journal of Multidisciplinary Healthcare
Abstract:Luyang Zhang, 1, &ast Li Wang, 2, &ast Jiewen Long, 1 Yan Yin, 1 Sandip Patil 1 1 Department of Haematology and Oncology, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, 518000, People's Republic of China; 2 Department of Clinical Nutrition, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, 518000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Sandip Patil; Yan Yin, Department of Haematology and Oncology, Shenzhen Children's Hospital, 7019 Yitian Road, Shenzhen, Guangdong Province, 518000, People's Republic of China, Tel +86-755-83008283, Email ; Objective: This retrospective study evaluated nutritional status and body composition changes in paediatric β-thalassemia (β-TM) patients before and after hematopoietic stem cell transplantation (HSCT), using bioelectrical impedance analysis (BIA), and explored their relationship with HSCT outcomes. Methods: A cohort of 40 paediatric β-TM patients undergoing allogeneic HSCT was assessed for their nutritional status, anthropometric parameters, including body mass index (BMI), weight, and height, and body composition parameters pre-and post-HSCT, focusing on BIA measurements, including intracellular water (ICW), extracellular water (ECW), fat mass (FAT), fat-free mass (FFM), Skeletal Muscle Mass (SMM), soft Lean Mass (SLM), percent body fat (PBF), Body Cell Mass (BCM), Phase angle (PA) and muscle balance pre- and post-HSCT. Post-HSCT clinical outcomes, including acute graft-vs-host disease (aGVHD), engraftment time, oral mucositis (OM), sinusoidal obstruction syndrome (SOS), and diarrhoea in relation to nutrition status after HSCT were analysed. Results: After HSCT, 28.21% experienced diminished nutritional status, with 71.43% of those who were wasting before HSCT showing diminished nutritional status, significantly higher than the normal group (18.75%, P = 0.012). Anthropometric changes included significant weight reduction (87.5%, 22.15 ± 7.46 vs 20.74 ± 6.57, P < 0.001) and BMI decrease (90%, 15.19 ± 1.70 vs 14.05 ± 1.48, P < 0.001). Body composition parameters, which are FFM, SMM, SLM, ICW, ECW, BCM, and PA (18.26 ± 5.71 vs 17.27 ± 5.19, 8.68 ± 3.30 vs 7.93 ± 3.02, 17.11 ± 5.28 vs 16.06 ± 4.84, 8.19 ± 2.54 vs 7.62 ± 2.31, 5.15 ± 1.58 vs 4.94 ± 1.47, 11.74 ± 3.63 vs 10.92 ± 3.32, 4.42 ± 0.50 vs 3.90 ± 0.57, respectively, P < 0.001) analysis revealed significant decreases. No significant differences in clinical outcomes were observed based on nutritional status. Conclusion: Paediatric β-TM patients undergoing HSCT exhibit significant changes in nutrition status and body composition, emphasizing the need for focused attention on malnourished children who are more prone to diminished nutritional status. Comprehensive BIA aids in understanding the impact, urging consideration for extended follow-up and larger cohorts in future research. Keywords: paediatric β-thalassemia, hematopoietic stem cell transplantation, HSCT, bioelectrical impedance analysis, BIA, nutritional status, malnourished children The term "thalassemia" refers to a group of inherited disorders characterized by defective production of haemoglobin (Hb). 1 Among these, β-thalassemia (β-TM) necessitates lifelong blood transfusions for survival. Allogeneic hematopoietic stem cell transplantation (HSCT) stands as the sole definitive cure for addressing defective erythropoiesis in children with β-TM. It offers respite from the lifelong demands of treatment and mitigating long-term complications associated with the disease or its therapeutic intervention. 2,3 The success of HSCT is intricately linked to the nutritional status of patients, with poor nutrition correlating with adverse outcomes such as relapse, non-relapse mortality, delayed engraftment, and an increased risk of acute graft-vs-host disease (aGVHD). 4–7 While the majority of HSCT patients exhibit good nutritional status prior to the procedure, with ~10% to 15% experiencing malnutrition. 8,9 Notably, β-TM patients often manifest growth retardation symptoms prior to HSCT, including shorter stature, being underweight, wasting away, and diminished bone mineral density. 10 The initiation of treatment, however, precipitates rapid deterioration of nutritional status, exposing patients to the perils of malnutrition. 7 Recognizing malnutrition through validated screening tools before HSCT and implementing timely interventions are pivotal in optimizing HSCT outcomes. Conventional Indicators like albumin, transferrin, and pre-albumin, while commonly used to assess nutritional status, are susceptible to interference from non-n -Abstract Truncated-
health care sciences & services
What problem does this paper attempt to address?